A Food and Drug Administration advisory panel recommended Wednesday that silicone gel implants made by Mentor Corp. be allowed back on the market for wider use -- a surprise decision that came a day after the same panel rejected the application of a rival company.
The panel voted, 7-2, in favor of lifting the 13-year-old partial ban on the controversial implants, but it also recommended that the company be required to meet nine tough conditions.
Wednesday's vote, coming after the same panel rejected the application of Inamed Corp. by a 5-4 vote, gives the FDA a mixed recommendation as it grapples with the future of the implants, used for breast enlargement and reconstructive surgery.
In 2003, the agency rejected an earlier advisory panel's recommendation to allow general use of silicone gel implants, and it could now decide to approve one company's device, both companies' devices or none.
Mentor officials were delighted by the panel vote.
"We're very gratified that the panel came to the decision they did and hopeful the agency will focus on the same things -- the quality of our science and the quality of our data on safety and efficacy," said Joshua Levine, president and CEO of California-based Mentor.
"I think the panel concluded that not all breast implants are created equally and not all test methods are created equally," Levine said.
In explaining their decision, several panel members said they were more impressed by Mentor's data on how and why implants rupture and by the lower rupture rate of its implants. While Inamed reported a yearly rupture rate of about 1.4 percent, the yearly Mentor rate was 0.2 percent -- a figure that had been questioned by FDA reviewers.
The panel decision was sharply questioned by Inamed officials, who had been criticized the day before for not having sufficiently long-term data.
"I am stunned by a bizarre and inexplicable decision by some panelists, who yesterday were demanding long-term data and today accepted shorter-term data," Dan Cohen, Inamed's vice president for global, corporate and government affairs, told Bloomberg News after the meeting in Gaithersburg, Md. "They had partial three-year data, and we have four-year data. Our rates are similar."
About 260,000 American women had their breasts enlarged with implants last year, and an additional 60,000 had received them after surgery for breast cancer.
Because of health concerns, the FDA in recent years has allowed silicone gel implants to be used only in women who had mastectomies and in some who take part in clinical trials; all others received implants filled with a saline solution.
Many women say the silicone gel looks and feels more natural, and it is widely used in other parts of the world.
The panel's decision was criticized by some public interest groups that have long argued that the potential dangers of silicone gel implants remain insufficiently studied.
Among the conditions recommended by the panel are that the company allow its devices to be implanted only by certified plastic surgeons who have worked with the devices before; that a major study of the implants be continued until the devices have been in use for 10 years; and that the implants be subjected to another FDA review in five years.
Laurie Casas, a plastic surgeon and spokeswoman for the American Society for Aesthetic Plastic Surgery, said that her organization would be working with plastic surgeons to set up a new certification program.
"We'll be working with the manufacturer and the FDA to fulfill whatever the agency requires to allow women to finally have a choice," she said. "We're very, very happy about this. Our hands have been tied for so long."